Calithera Biosciences, Inc. (CALA - Free Report) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CALA’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Calithera Biosciences could be a solid choice for investors.
Current Quarter Estimates for CALA
In the past 30 days, one estimate has gone higher for Calithera Biosciences while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 34 cents a share 30 days ago, to a loss of 29 cents today, a move of 14.7%.
Current Year Estimates for CALA
Meanwhile, Calithera Biosciences’ current year figures are also looking quite promising, with one estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.21 per share 30 days ago to a loss of 96 cents per share today, an increase of 20.7%.
Calithera Biosciences, Inc. Price and Consensus